


DIGNITANA

Clinically superior scalp cooling

16 FEBRUARY 2023

**Focused growth
of 25 percent:
Scaling up with a
commitment
to patients**



Q4 22

YEAR END REPORT

Focused growth of 25 percent: Scaling up with a commitment to patients

Financial highlights Q4 2022

- Net sales amounted to 20.2 MSEK (16.2), an increase of 25 percent over the same period in 2021.
- Operating result amounted to -10.9 MSEK (-11.4).
- Net result after financial items amounted to -12.9 MSEK (-11.8).
- Earnings per share were -0.17 SEK (-0.10).
- Cash Balance amounted to 8.9 MSEK (14.5).
- Average Daily Treatment Revenue (ADTR)* was 229 TSEK (155), an increase of 48 percent over the same period in 2021.

Financial highlights January - December 2022

- Net sales amounted to 73.0 MSEK (57.1), an increase of 28 percent over the same period in 2021.
- Operating result amounted to -20.6 MSEK (-41.6).
- Net result after financial items amounted to -22.4 MSEK (-43.1).
- Earnings per share were -0.34 SEK (-0.66).

Significant events during the period

- In October Dignitana announced a directed share issue of approximately 25 MSEK.

Business highlights during the period

- Dignitana appointed the Nomination Committee for the 2023 Annual General Meeting.
- Dignitana CEO Catarina Löwenadler was featured at the Aktiespararna Women's Night in Stockholm.
- In November Dignitana was featured at Stora Aktiedagen in Stockholm.
- Dignitana appointed Johan Johansson as VP Operations, Research and Development.

Business highlights after the period

- Dignitana's prominent visibility in the breast cancer community continued with the Susan G. Komen® More Than Pink Walk in West Palm Beach, Florida.

"Patient satisfaction fuels the passion of our team, keeping us laser-focused on continuing to grow Dignitana to its full potential."
- Catarina Löwenadler, CEO

Key Figures

DIGNITANA GROUP	Q4 2022	Q4 2021	Full year 2022	Full year 2021
Net sales, TSEK	20,245	16,213	72,995	57,073
Total revenues, TSEK	21,421	17,322	83,849	62,376
Net profit after financial items, TSEK	-11,996	-11,836	-22,396	-43,077
Cash and bank balances, TSEK	8,869	14,501	8,869	14,501
Earnings per share, SEK	-0.17	-0.18	-0.34	-0.66
Average Daily Treatment revenue, TSEK	229	155	203	147

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

DIGNITANA AB IS A SWEDISH MEDICAL TECHNOLOGY COMPANY THAT PRODUCES AND MARKETS THE DIGNICAP SCALP COOLING SYSTEM TO MINIMIZE HAIR LOSS DURING CHEMOTHERAPY AND IMPROVE WELL-BEING AND QUALITY OF LIFE FOR CANCER PATIENTS.

Focused growth of 25 percent: Scaling up with a commitment to patients

Dignitana's vision is to ensure every single cancer patient can maintain dignity and quality of life during and after cancer treatment. This is a significant aspiration, and I am pleased that our focused work and accomplishments in 2022 have brought us closer to achieving this vision. I want to also highlight the passion of both our patients and team members. Nearly every week we are honored to hear from patients who share how DigniCap has positively impacted their quality of life during cancer treatment, allowing them to maintain their privacy, identity and control during a very difficult time. These patient stories, which we feature on our blog and in social media, are what fuel the passion of our team, keeping us laser-focused on continuing to grow Dignitana to its full potential.

Utilization drives growth

Our fourth quarter closed with an increase in net sales of 25 percent over the same period in 2021. This growth is primarily due to a 48 percent increase in the fourth quarter Average Daily Treatment Revenue in our key U.S. market. The Company's strategy to increase utilization is working, along with our focus on clinics with potential for high patient volumes.

Funding raised in the fourth period has been allocated to acceleration of device production to meet growing demand. In addition to devices for new locations, clinics are now frequently adding additional units as their usage increases. To provide the market with a more detailed picture of growth, we will now include this same-site expansion in our Investor Newsletter.

It is worth noting that we have seen some supply chain issues through the fourth period and anticipate some of these delays will persist into 2023. However, our Operations team is working diligently to address these challenges to ensure that growing number of DigniCap customers have the products and supplies that are needed.

Increasing awareness

A significant portion of funds from the recent directed share issue were allocated to marketing initiatives to further expand awareness of DigniCap among patients and healthcare providers. In the fourth period we participated in several events to keep that momentum growing including the San Antonio Breast Cancer Symposium, Susan B. Komen More Than Pink Walk in Los Angeles, Hair To Stay Fundraiser in San Francisco, and Joe Arrington House Concert in Lubbock. We kicked off 2023 with a large Susan B. Komen event in Florida. This spring we are exhibiting at two national oncology nursing conferences in the U.S. and are excited to be exhibiting at an Oncology Nursing conference in Sweden as well.

Addressing affordability

Affordability is a key factor in a patient's decision to use DigniCap, with reimbursement as a primary component. The "Buy and Bill" business model we launched last fall is the

pathway for providers to submit claims for the specialized scalp cooling service they provide. This model is a change in how we do business with our customers, and changes take time - but we are seeing progress with providers who are filing claims, both in frequency as well as the outcome of claims with a wide range of payers including Medicare. To further support affordability Dignitana works with over a dozen foundations across the U.S. who provide financial assistance to patients interested in using DigniCap.

Global growth

As our home market, Europe is also a strong priority for the company. The addition of a new VP Sales for Europe in the last period provided increased activity, building a platform for accelerated growth. There is significant interest in the DigniCap product across Europe, and already two locations in Italy added devices in the fourth period, with media coverage of those installations further enhancing interest and awareness. We are excited at the enthusiasm from clinicians at cancer clinics across Europe and are working strategically to optimize this regional growth channel.

Customer satisfaction

DigniCap Direct is officially a hit with customers! This unique partner portal provides busy nurses with one-stop access to DigniCap training, ordering and resources. Streamlining these processes has also increased efficiencies among our team, and we are excited to expand DigniCap Direct for use by healthcare providers and distributors around the globe this year.

On the consumer side, a recent survey of DigniCap patients showed a customer satisfaction score of 97 percent. This is a testament to our strong commitment to customer service coupled with a superior product, and we are proud that nearly ALL Dignitana patients would recommend DigniCap to someone else.

Focus on the future

The capital raised in the fourth quarter provides a firm foundation for accelerated growth, and we are confident in both the strategy and tactics we have underway. We appreciate the support of our shareholders and look forward to continued growth and expansion in 2023.



Catarina Löwenadler, CEO
Dignitana AB

The Company

Dignitana AB is a medical technology company based in Lund, Sweden and publicly traded on Nasdaq First North Growth Market in Sweden. Company headquarters are in Lund, Sweden and U.S. operations are based in Dallas, Texas. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Redeye AB is Certified Adviser.

The Company produces The DigniCap Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. The DigniCap Scalp Cooling System was invented in 1999 by a Swedish oncology nurse.

DigniCap has been on the market in Europe since 2001 and has had FDA clearance since 2015 to provide continuous scalp cooling with high efficacy, safety, and acceptable patient comfort. In 2017 Dignitana received expanded clearance from the FDA allowing DigniCap to be used by patients receiving chemotherapy to treat other solid

tumors in addition to the original indication for use by patients with breast cancer. In 2019 Dignitana introduced the next generation DigniCap Delta. The technologically advanced DigniCap Delta model received CE Marking and FDA clearance that year, as well as regulatory approvals in Australia and Israel.

Scalp cooling is recognized as standard of care by numerous organizations around the world. European Society for Medical Oncology (ESMO) added scalp cooling as a Category IIB treatment recommendation in 2020 and Cancer Australia added scalp cooling to its Fall 2020 update providing guidance for the management of early breast cancer patients. In the United States clinical recommendations introduced in 2019 and 2020 by the National Comprehensive Cancer Network® and a policy reaffirmation by the American Medical Association in 2022 all contribute to a solid foundation for scalp cooling to become standard of care in the United States.


Business model

Dignitana has two business models that each include an ongoing revenue stream from the sale of consumables.

In the United States devices are leased to providers and the Company utilizes a pay-per-treatment model. The availability of scalp cooling continues to expand as we work toward scalp cooling becoming standard of care providing access to more patients. Dignitana also offers a buy and bill model that supports reimbursement initiatives. As reimbursement and coverage become more predictable, we

anticipate providers will transition to this widely accepted business model.

Outside the U.S. devices are sold to medical facilities and the company also receives revenue from service and maintenance agreements. For global markets that do not have a pay-per-treatment model, the focus is on creating a more sustainable recurring revenue stream from unit sales, lease agreements, service and maintenance fees, and sales of product disposables and supplies.



Reimbursement

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability. Health care providers are key partners in our efforts to increase accessibility to improve quality of life for as many cancer patients as possible. Dignitana recognizes that providers allocate a range of resources to scalp cooling therapy and their clinical expertise, direct patient care, and skilled operation of the DigniCap device by trained personnel ensure that DigniCap patients have the most successful clinical outcomes possible. The buy and bill model Dignitana offers facilitates a pathway for providers to be reimbursed for the specialized service they are providing to patients.

Dignitana has led the way in reimbursement efforts for scalp cooling in the U.S., including work supporting the 2021 introduction of CPT® codes for scalp cooling and a rate assignment from the Centers for Medicare & Medicaid Services (CMS) that was introduced in 2022. Dignitana continues to work with healthcare providers and payers to advance reimbursement of scalp cooling.

Dignitana is committed to ensuring scalp cooling is available to every cancer patient and reimbursement is a critical factor in patient access and affordability.



”

My wedding was after chemo number 6 (out of 8 total). With each passing treatment I worried that I would have to get married in a wig.

Thankfully, DigniCap worked!

Allison, Colorado

The market

The market

DigniCap minimizes chemotherapy-induced hair loss for cancer patients with solid tumors.

Globally there are over 17 million incidences of cancer diagnosed annually, with 1.9 million diagnoses occurring in the U.S. each year, and by 2040 the global cancer burden is projected to reach 28 million new incidences solely due to growth and aging of the population. In the U.S. it is estimated that 39 out of 100 women and 40 out of 100 men will develop cancer during their lifetime.

Scalp cooling is primarily used today during the treatment of breast cancer, the most common type of cancer in

the world. Globally 2.3 million cases of breast cancer are diagnosed annually, with 291,000 of those in the United States. Scalp cooling is also used by patients with other solid tumors such as ovarian, uterine, endometrial, cervical, and prostate cancers. Non-breast solid tumors represent nearly one million patients in the U.S annually.

Dignitana estimates that up to 60 percent of all cancer patients are on regimens that are compatible with DigniCap. Additionally published studies have found that 8-10% of female patients refuse chemotherapy due to concern over hair loss, and 96 percent of potential patients surveyed were interested in scalp cooling.

Market development

The DigniCap Scalp Cooling System is clinically proven to reduce hair loss in cancer patients undergoing chemotherapy for solid tumors. The DigniCap Scalp Cooling System has been marketed worldwide since 2009 and received FDA clearance for the US market in 2015. DigniCap was the first scalp cooling system to receive FDA clearance, with only two other systems now on the market that received clearance more recently.

The DigniCap Delta model was introduced in 2019 and is a smaller, single-patient device providing optimal outcomes and improved ease of use for clinicians and patients. In 2019 DigniCap Delta received CE Marking for Europe and FDA clearance for the U.S., followed by TGA clearance for Australia.

To increase awareness and utilization of scalp cooling Dignitana works with patient advocacy organizations and interest groups in the cancer care community. Dignitana's ongoing sponsorship of Susan G. Komen, the largest breast cancer advocacy group in the world, is an example of this, in addition to numerous partnerships with foundations across the United States.

In most of the world scalp cooling is not a standard option for cancer care. The acceptance, market penetration and utilization of this treatment vary widely, providing significant opportunities for Dignitana all over the world.

Dignitana is committed to advancing the science of scalp cooling by supporting clinical trials and research initiatives among DigniCap users. The Company has initiated several studies that could expand usage to new user groups and show improvements with existing regimens that have exhibited inferior results with scalp cooling previously.



Financial information and comments

DIGNITANA GROUP

Revenues

Group revenues are generated by direct sales of systems, leasing of systems to health care providers, pay-per treatment fees, service and maintenance agreements, sales of individual caps and kit accessories. For the fourth quarter 2022 net sales amounted to 20,245 TSEK (16,213), an increase over the same period 2021 by 4,032 TSEK representing 25 percent growth. For the full year 2022 net sales reached 72,995 TSEK (57,073), an increase by 28% compared to 2021.

Dignitana operates by two business models: in the U.S. market DigniCap Delta systems are leased to health care providers and the Company generates revenues from the leasing contracts through monthly leasing fees as well as payment for treatments and sales of products related to patient treatments. Outside the U.S, revenues are generated by sales of DigniCap Delta systems, frequently combined with service and maintenance agreements, as well as the sale of patient-related products and consumables.

The U.S. market is still the driver in placing DigniCap Delta on the market using the leasing business model. So far in 2022 the Company has continuously focused on reallocating weak utilized machines in some facilities to higher usage facilities with increasing demand. This enables the Company to reach more patients and improve patient outcomes and thereby achieve higher growth. Reallocation of devices to optimize utilization will continue as part of normal business operations as the market develops.

Dignitana's revenue and costs comprise of different currencies such as USD, EUR, and SEK. Operational exchange rate balance effects are recognized in the income statement under other operating income and in other operating expenses. In the fourth quarter 2022 net exchange rate effects amounted to -125 TSEK (11). For whole 2022 the operational exchange effect landed at +9,428 TSEK. Internal loans were redirected from USD to SEK during Q4 and this will reduce the revaluation effect related to exchange fluctuations going forward.

Operating Expenses and Operating Result

Operating expenses including Personnel expenses decreased during the quarter compared to the same period last year by 990 TSEK and amounted to -19,409 TSEK (-20 399). Q4 includes reserve for severance of -1.1 MSEK. We are increasing activities supporting sales growth and consequently travel and marketing costs are expected to increase.

Operating expenses for the year 2022 decreased versus 2021 by 6,867 to -63,615 TSEK (-70,482). In 2022 the costs for quality and regulatory has been normalized to a lower level. Reorganization of the Group has been established to focus on cost efficiency in internal processes.

Depreciation and amortization in the Group amounted to -3,677 TSEK (-3 286).

The operating result after depreciation for the Group was for the fourth quarter -10,927 TSEK (-11,417). An inventory write-down of -1.6 MSEK related to spare parts for old equipment affects the result in Q4. For the whole year 2022 the operating loss after depreciation was halved to -20,614 TSEK (-41,554) compared to the year before. The result improves mainly due to increased turn over during the year and increased utilization of the existing assets in US.

Financial net

The financial net was -1,069 TSEK (-419), affected negatively by exchange adjustment of an inter-company loan. The financial net for the full year was -1,782 TSEK (-1,522) and is mainly affected by debt-related interest in the U.S. and on the bridge loan from Agartha as well as a positive net on the exchange effects on bank accounts.

Employees

At the close of the period the Company had 29 (25) employees.

Cash Flow and Financial Position

Consolidated cash flow from operating activities during the quarter was -7,557 TSEK (-11,880). Total cash flow for the period was 2,260 TSEK (-5,525), including a directed right issue of net 23,4 MSEK and repayment of bridge loan -10 MSEK to Agartha. Cash and cash equivalents at the end of the quarter amounted to 8,869 TSEK (14,501). Total cash flow for 2022 ended at -6,264 TSEK (-61,750) including amortization to credit institutions at -8,685 TSEK.

Board and Management are continuously monitoring the financial position of the Company and are of the opinion that current business plans combined with the direct share issue performed in October are sufficient financial resources to cover working capital needs for the coming 12-month period.

CAPEX

Capex amounted to 1,326 TSEK (1,123) in the quarter, and for the total year 3,149 TSEK (-10,556), mainly in tangible assets in US and intangible assets in the parent company in Sweden.

The share

Dignitana has been listed on First North Growth Market since November 2011 after having been listed on Spotlight Market in Stockholm since June 2009.

Dignitana AB

TICKER	DIGN
Market Cap December 31	362 MSEK
Number of shareholders, approximately	2,413
Share price December 31	5.13 SEK
Number of shares traded during the quarter	1,633 135
Number of shares outstanding September 30	70,474,155
Registered share capital	7,047,416 SEK
Par value	0.1 SEK
Certified Adviser	Redeye

Dignitana has only one category of shares, where each share carries one vote and equal rights to the Company's assets and profits. The Company has over time issued new shares and stock option programs and in February 2020 an extraordinary general meeting was held where a decision was taken to issue a maximum of 2,500,000 employee warrants to key employees of the Company. The period for exercising the employee stock warrants will run from 1 March 2023 to 31 March 2023. The employee warrants were granted gratuitously and yearly costs of 960 TSEK are booked continuously.

Largest Shareholders

30 DECEMBER 2022	HOLDINGS	PERCENT
AGARTHA AB	20,500,000	29.09%
SWEDBANK ROBUR MICROCAP	5,415,000	7.68%
HANDELSBANKEN MICROCAP SVERIGE	5,350,000	7.59%
AVANZA PENSION	4,692,221	6.66%
CBLDN-UBS FINANCIAL SERVICES INC	4,189,739	5.95%
FÖRSÄKRINGSAKTIEBOLAGET SKANDIA (PUB	2,607,835	3.70%
FE SMÅBOLAG SVERIGE	1,800,000	2.55%
TECHNOVOBIS AB	1,790,593	2.54%
POURSAMAD, AMIR	1,445,124	2.05%
RÜLF, SEMMY	1,015,058	1.44%
TOTAL	48,805,570	69.25%
OTHER SHAREHOLDERS	21,668,585	30.75%
TOTAL	70,474,155	100.00%

Source: Euroclear

Risk factors

An investment in securities is associated with risk. Dignitana's activities are affected, and may be affected, by several factors which cannot be completely controlled by the Company. There are risks both in terms of circumstances attributable to Dignitana and those which have no specific connection with the Company.

The non-definitive list of the Company's risks pertains, but is not limited, to: patents, key personnel, growth management, management, restructuring, development costs, competitors, dependence on individual customers, customers, authorization and registration, chemotherapy without side effects, alternative cancer treatment

methods, distributors and manufacturers, profitability and future capital requirements, political risk, geopolitical risks, pandemic risks, regulatory or change of laws, disputes and currency risks.

Risks related to COVID-19

The outbreak of COVID-19 in the spring of 2020 has affected the Company's opportunities to reach customers but also customers' ability to offer scalp cooling as a form of treatment. The Company has therefore been impacted financially, although it is not possible to make a full assessment.

Risks related to the Russian invasion of Ukraine

The company's assessment is that the ongoing military conflict in Ukraine, should not have any immediate significant effect on the operations. Indirect effects such as increases in energy costs and transportation, increased lead time of components and general cost increases could have some impact on the operations but are deemed as manageable. If the conflict spreads to more territories, this assessment could change. USA is the group's primary market from a sales and supply perspective.

The Board is ultimately responsible for managing and monitoring these risks. Ongoing management is delegated to the CEO, who in turn reports to the Board.

For a detailed explanation of these risk factors view the 2021 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

Other information

Forward-looking statements

This report may contain statements, estimates or projections that constitute "forward-looking statements." Generally, the words "believe", "expect", "intend", "estimate", "anticipate", "project", "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the Dignitana historical experience or future projects.

Accounting principles

The consolidated financial statements comprise of Dignitana AB and its subsidiaries Dignitana Inc. and Dignitana S.r.l.

This interim report is prepared in accordance with Swedish GAAP, BFNR 2012:1 (K3). The accounting policies remain unchanged compared with the preceding year and are the same principles that were applied for the Annual Report 2021.

Financial statements are presented in SEK, the functional currency of Dignitana AB. Assets and liabilities are translated and presented at the closing rate and the Income statement is translated and presented at period average exchange rates.

For a detailed explanation of accounting principles view the 2021 Annual Report posted at <https://dignitana.com/investor-relations/financial-reports/>

This Interim Report has not been reviewed by the Group's Auditors.

Board assurance

The Board of Directors and Chief Executive Officer declare that this Interim Report provides a fair view of the Company's operations, financial position and results, and describes material risks and uncertainties facing the Company.

Dignitana AB

Corporate Registration Number: 556730-5346

Lund, 16 February 2023

Dignitana AB (publ) Board of Directors

Klas Arildsson
Chairman of the Board

William Cronin
Deputy Chairman of the Board

Richard Dilorio
Board member

Lina Karlsson
Board member

Christian Lindgren
Board member

Ljubo Mrnjavac
Board member

Income Statement – Dignitana Group, TSEK

DIGNITANA GROUP	Q4 2022	Q4 2021	Full year 2022	Full year 2021
Operating Income				
Net sales	20,245	16,213	72,995	57,073
Capitalized work for own account	431	0	431	0
Other operating income	745	1,109	10,423	5,303
Total Operating Income	21,421	17,322	83,849	62,376
Operating expense				
Goods for Resale	-9,262	-5,054	-27,049	-20,711
Operating expense	-8,023	-8,235	-28,579	-30,053
Personnel expense	-11,085	-8,101	-34,289	-30,386
Depreciation and amortization of tangible and intangible assets	-3,677	-3,286	-13,799	-12,737
Other operating expenses	-301	-4,063	-747	-10,043
	-32,348	-28,739	-104,463	-103,930
Operating profit (loss)	-10,927	-11,417	-20,614	-41,554
Result from financial investments				
Other Interest income and similar items	15	25	616	118
Interest expenses and similar items	-1,084	-444	-2,398	-1,640
	-1,069	-419	-1,782	-1,522
Profit after financial items	-11,996	-11,836	-22,396	-43,077
Profit before tax	-11,996	-11,836	-22,396	-43,077
Tax on profit for the period	-15	-10	-15	-10
Results for the Period	-12,011	-11,846	-22,411	-43,086
Average number of shares	69,343,551	65,059,155	66,130,254	65,059,155
Earnings per share, SEK	-0.17	-0.18	-0.34	-0.66

Balance Sheet – Dignitana Group, TSEK

DIGNITANA GROUP	2022-12-31 2022	2021-12-31 2021
ASSETS		
FIXED ASSETS		
Intangible assets		
Capitalized expenses for development	7,139	11,189
	7,139	11,189
Tangible assets		
Equipment, tools and installations	164	187
Machinery and other technical facilities	27,006	30,104
	27,170	30,291
Financial assets		
Other long term receivables	175	0
	175	0
Total Fixed Assets	34,484	41,480
CURRENT ASSETS		
Inventories and similar		
Finished goods and goods for resale	5,053	7,120
	5,053	7,120
Current Receivables		
Accounts Receivable	6,505	5,103
Current Tax Assets	123	66
Other Current Receivables	756	862
Prepaid expenses and accrued income	2,884	2,222
	10,268	8,253
Cash and Bank Balances	8,869	14,501
Total Current Assets	24,190	29,874
Total Assets	58,674	71,354
EQUITY AND LIABILITIES		
Equity		
Share Capital	7,047	6,506
Unregistered share capital	0	0
Ongoing new issue	0	0
Other contributed capital	245,866	222,692
Other equity including profit for the year	-228,663	-198,012
Total Equity	24,250	31,186
Provisions		
Other provisions	187	69
	187	69
Long Term Liabilities		
Other long term liabilities	8,614	15,828
Total Long Term Liabilities	8,614	15,828
Current Liabilities		
Liabilities to credit institutions	9,653	7,762
Accounts payable	5,575	6,234
Other current liabilities	1,488	761
Accrued expenses and deferred income	8,907	9,514
Total current liabilities	25,623	24,271
Total liabilities	34,237	40,099
Total Equity and Liabilities	58,674	71,354

Consolidated Statement of Changes in Equity

– Dignitana Group, TSEK

DIGNITANA GROUP	Share capital	Other contributed capital	Retained earnings, incl. net loss for the year	Total equity
Opening equity on 1/1/2021	6,506	222,692	-151,562	77,636
Net loss for the year			-43,086	-43,086
Option program 2021			960	960
Change in translation difference relating to subsidiaries			-4,324	-4,324
Closing equity on 12/31/2021	6,506	222,692	-198,012	31,186
Net loss for the period			-22,411	-22,411
Share warrants		378		378
Option program 2022			960	960
New share issue	541	24,314		24,855
Issue costs		-1,518		-1,518
Change in translation difference relating to subsidiaries			-9,200	-9,200
Closing equity on 12/31/2022	7,047	245,866	-228,663	-6,426

Statement of Cash Flows – Dignitana Group, TSEK

DIGNITANA GROUP	Q4 2022	Q4 2021	Full year 2022	Full year 2021
Operating activities				
Profit after financial investments	-11,996	-11,836	-22,396	-43,076
Adjustments for items not affecting cash flows, etc	5,218	4,724	6,106	12,288
Tax paid	-17	25	-59	-80
Cash flow from operating activities before changes in working capital	-6,795	-7,087	-16,349	-30,868
Cash flow from changes in working capital				
Change in inventories	1,305	-216	813	-467
Change in other current receivables	-593	9	-1,684	422
Change in other current liabilities	-1,474	-4,586	-1,016	-12,960
Cash flows from operating activities	-7,557	-11,880	-18,236	-43,873
Investing activities				
Investments in intangible assets	-431	0	-431	0
Proceeds from sale of intangible assets	0	0	0	0
Investments in tangible assets	-895	-1,123	-2,718	-10,556
Proceeds from sale of tangible assets	91	0	91	0
Cash flows from investing activities	-1,235	-1,123	-3,058	-10,556
Financing activities				
New share issue	24,855	0	24,855	0
Issue expenses	-1,437	0	-1,518	0
Options issued	0	0	378	0
New loans	0	0	10,000	0
Repaid loans	-10,000	0	-10,000	-20,000
Changes in long and short term liabilities to credit institutions	-2,366	7,478	-8,685	12,679
Cash flow from financial activities	11,052	7,478	15,030	-7,321
Cash flow for the period	2,260	-5,525	-6,264	-61,750
Cash and cash equivalents at beginning of period				
Cash and cash equivalents at beginning of period	6,737	21,047	14,501	78,770
Exchange-rate differences in cash and cash equivalents				
Exchange-rate differences in cash and cash equivalents	-128	-1,021	632	-2,519
Cash and cash equivalents at end of period	8,869	14,501	8,869	14,501

Income Statement – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	Q4 2022	Q4 2021	Full year 2022	Full year 2021
Operating Income				
Net sales	3,789	17,690	12,140	37,743
Capitalized work for own account	431	0	431	0
Other operating income	60	952	9,454	1,940
Total Operating Income	4,280	18,642	22,025	39,683
Operating expense				
Goods for Resale	-3,197	-524	-5,911	-7,179
Operating expense	-13,658	-21,989	-21,666	-41,512
Personnel expense	-4,182	-1,619	-10,243	-5,367
Depreciation and amortization of tangible and intangible assets	-1,144	-3,234	-6,659	-12,517
Other operating expenses	-159	-1,741	-431	-3,430
	-22,340	-29,107	-44,910	-70,005
Operating profit (loss)	-18,060	-10,465	-22,885	-30,322
Result from financial investments				
Other Interest income and similar items	391	24	992	118
Interest expenses and similar items	-696	-14	-712	-473
	-305	10	280	-355
Profit after financial items	-18,365	-10,455	-22,605	-30,677
Profit before tax	-18,365	-10,455	-22,605	-30,677
Tax on profit for the period	0	0	0	0
Results for the Period	-18,365	-10,455	-22,605	-30,677

Balance Sheet – Dignitana AB, TSEK

DIGNITANA AB, PARENT COMPANY	2022-12-31	2021-12-31
ASSETS		
FIXED ASSETS		
Intangible assets		
Capitalized expenses for development	7,116	11,165
	7,116	11,165
Tangible assets		
Equipment, tools and installations	0	0
Machinery and other technical facilities	114	30,104
	114	30,104
Financial assets		
Participations in group companies	66,198	522
Receivable from group companies	10,698	452
Other long term receivables	175	0
	77,071	974
Total Fixed Assets	84,301	42,243
CURRENT ASSETS		
Inventories and similar		
Finished goods and goods for resale	2,766	5,289
	2,766	5,289
Current Receivables		
Accounts Receivable	1,470	1,927
Receivables from group companies	0	26,992
Current Tax Assets	123	117
Other Current Receivables	666	772
Prepaid expenses and accrued income	446	854
	2,705	30,662
Cash and Bank Balances	5,455	9,239
Total Current Assets	10,926	45,190
Total Assets	95,227	87,433
EQUITY AND LIABILITIES		
Equity		
Restricted equity		
Share Capital	7,047	6,506
Unregistered share capital	0	0
Fund for development expenses	7,116	11,165
	14,163	17,671
Non-restricted equity		
Share premium reserves	245,866	222,692
Other non-restricted equity	-156,070	-129,442
Results for the period	-22,605	-30,677
	67,191	62,573
Total Equity	81,354	80,244
Provisions		
Other provisions	175	0
	175	0
Current Liabilities		
Accounts payable	921	2,124
Current payable to group company	6,592	0
Other current liabilities	924	129
Accrued expenses and deferred income	5,261	4,936
Total current liabilities	13,698	7,189
Total liabilities	13,698	7,189
Total Equity and Liabilities	95,227	87,433

Financial calendar

4 May 2023	2022 Annual Report
25 May 2023	Q1 Report
25 May 2023	Annual General Meeting
17 August 2023	Q2 Report
16 November 2023	Q3 Report
15 February 2024	2023 Year End Report

All financial reports are available at
www.dignitana.com/investor-relations/financial-reports/

Contact information

Dignitana AB

Traktorgränden 3, 226 60 Lund
+46 (0) 46-16 30 90
info@dignitana.com
investorrelations@dignitana.com
www.dignitana.com

Certified Adviser

Redeye AB
+46 8 121 576 90
certifiedadviser@redeye.se
www.redeye.se